Tirzepatide vs Retatrutide: Which Weight Loss Drug Works Better?

Tirzepatide (Zepbound) is currently the most effective weight loss medication available, producing roughly 20% mean weight reduction in clinical trials. Retatrutide, Eli Lilly's next-generation triple agonist, has posted Phase 2 results that exceed those numbers — and Phase 3 data continues to mature through the TRIUMPH program. For patients and clinicians weighing the obesity treatment pipeline, the comparison between these two drugs is the most consequential question in the field.

This article breaks down what the science currently shows about tirzepatide vs retatrutide for weight loss, how their mechanisms differ, what the safety signals look like, and when retatrutide is likely to reach the market.

How These Drugs Work: Dual vs Triple Receptor Agonism

Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates two gut-hormone receptors simultaneously: glucagon-like peptide-1 (GLP-1), which reduces appetite and slows gastric emptying, and glucose-dependent insulinotropic polypeptide (GIP), which amplifies satiety signaling and improves insulin sensitivity. This dual mechanism is what gives tirzepatide its efficacy advantage over single GLP-1 agonists like semaglutide.

Retatrutide goes one step further. It is a triple agonist that engages GLP-1, GIP, and the glucagon receptor. The added glucagon component is the key differentiator. Glucagon increases resting energy expenditure, promotes lipolysis (fat breakdown), and accelerates hepatic fat clearance — effects that are absent from dual or single agonists. The net pharmacological result is a drug that not only suppresses intake (via GLP-1/GIP) but also burns more energy (via glucagon).

Whether this translates into a clinically meaningful real-world advantage is the question Phase 3 is designed to answer.

Phase 2 Efficacy: The NEJM Data

The most cited evidence on retatrutide comes from the Jastreboff et al. Phase 2 trial, published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity (BMI ≥30) or overweight with a comorbidity, randomized to placebo or once-weekly retatrutide at 1, 4, 8, or 12 mg for 48 weeks.

Evidence: "At week 48, the least-squares mean percentage change in body weight in the retatrutide groups was −8.7% with the 1 mg dose, −17.1% with 4 mg, −22.8% with 8 mg, and −24.2% with 12 mg, as compared with −2.1% with placebo." — Jastreboff AM, et al. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2301972

Tirzepatide's benchmark dataset is SURMOUNT-1, the registrational Phase 3 trial that supported FDA approval of Zepbound.

Evidence: "The mean percentage change in weight at week 72 was −15.0% with 5 mg tirzepatide, −19.5% with 10 mg, and −20.9% with 15 mg, as compared with −3.1% with placebo." — Jastreboff AM, et al. N Engl J Med. 2022. DOI: 10.1056/NEJMoa2206038

Direct comparison is imperfect — different trial durations (48 vs 72 weeks), slightly different populations, and different dose-escalation schedules. But the directional signal is consistent: retatrutide produces larger mean weight loss at its top dose than tirzepatide at its top dose, with the gap of roughly 3–4 percentage points.

Response Rate Comparison

The percentage of participants reaching specific weight-loss thresholds matters more clinically than mean values, because obesity treatment is highly responder-driven.

The retatrutide response curve does not appear to have plateaued at 48 weeks, raising the possibility that longer treatment could push mean weight loss higher — a hypothesis the Phase 3 TRIUMPH-4 trial (68 weeks at 12 mg) was designed to test.

Phase 3: The TRIUMPH Program

Eli Lilly's Phase 3 program for retatrutide is called TRIUMPH and includes multiple trials:

• TRIUMPH-1: Adults with obesity (no T2D)
• TRIUMPH-2: Obesity with osteoarthritis of the knee
• TRIUMPH-3: Obesity with established cardiovascular disease
• TRIUMPH-4: Maintenance and dose-response in obesity
• TRIUMPH-Outcomes: Cardiovascular outcomes trial

Topline TRIUMPH-4 data reported by Lilly showed mean weight loss approaching 28–29% at 68 weeks with the 12 mg dose — extending the Phase 2 trajectory and reinforcing the cross-trial comparison. The cardiovascular outcomes trial (TRIUMPH-Outcomes) will not read out until approximately 2027–2028 and is the regulatory gate for any MACE-reduction label claim.

For context, tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is also ongoing. Until both read out, neither drug has a confirmed major adverse cardiovascular event (MACE) benefit on the obesity label.

Liver Fat and Metabolic Disease

A Phase 2 substudy published in Nature Medicine in 2024 evaluated retatrutide's effect on metabolic dysfunction-associated steatotic liver disease (MASLD).

Evidence: "The mean relative change from baseline in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) and +0.3% (placebo) (all P < 0.001 versus placebo). At 24 weeks, normal liver fat (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), and 86% (12 mg) of retatrutide participants." — Sanyal AJ, et al. Nature Medicine. 2024;30(7):2037-2048. DOI: 10.1038/s41591-024-03018-2

These are the largest liver-fat reductions ever reported in a clinical trial of a metabolic drug. The likely driver is the glucagon receptor activity, which directly upregulates hepatic fatty acid oxidation. Tirzepatide also reduces liver fat substantially (~30–47% in MASH substudies), but the magnitude of retatrutide's effect is in a different range entirely — relevant for patients with fatty liver disease (MASLD).

Safety and Tolerability

Both drugs share the GLP-1 class side-effect profile, with gastrointestinal events being the dominant tolerability issue.

Tirzepatide GI Profile (SURMOUNT-1)

Evidence: "Nausea was reported in 24–33% of tirzepatide-treated participants versus 9.5% with placebo. Discontinuation due to adverse events occurred in 4.3–7.1% of tirzepatide groups versus 2.6% with placebo." — Rubino DM, et al. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.16176

Most GI events were mild to moderate and clustered during the 20-week dose-escalation period.

Retatrutide Profile and the Heart Rate Signal

Retatrutide's GI profile in Phase 2 was qualitatively similar — nausea, vomiting, diarrhea, and constipation, mostly during titration. Two additional signals warrant attention:

1. Heart rate increase. Retatrutide produced a dose-dependent rise in resting heart rate of approximately 6–7 beats per minute at the 8 and 12 mg doses, larger than the modest 2–4 bpm increase typically reported with tirzepatide. The clinical significance is not yet known and is being evaluated in TRIUMPH-Outcomes.
2. Glucagon-mediated glycemic effects. In patients without diabetes, fasting glucose increased modestly at the highest retatrutide doses — a predictable consequence of glucagon receptor activation. This did not translate into hyperglycemia in non-diabetic participants, but ongoing trials in patients with type 2 diabetes are evaluating net glycemic balance.

Neither drug has shown a thyroid C-cell tumor signal in humans, but both carry the GLP-1 class boxed warning based on rodent data and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Side-by-Side Tolerability

Retatrutide's higher discontinuation rate at the top dose largely reflects the steep dose-escalation protocol used in Phase 2. Phase 3 protocols use a slower titration schedule, which is expected to improve tolerability.

Approval Status and Access

This is the practical dividing line between the two drugs.

Tirzepatide is FDA-approved and commercially available as Zepbound (obesity, since November 2023) and Mounjaro (type 2 diabetes, since May 2022). It is on formulary at most major payers, has a manufacturer savings program, and is available at compounding pharmacies under specific FDA conditions during shortages.

Retatrutide is investigational. As of May 2026, Lilly has not filed a new drug application. Realistic projections place the earliest possible FDA approval in late 2027 — assuming TRIUMPH Phase 3 readouts continue to support filing. Until then, the only legitimate access is through clinical trial enrollment via ClinicalTrials.gov. Compounded "retatrutide" sold by online vendors is not FDA-approved, is often not the genuine molecule, and carries serious safety risks.

For patients who need treatment now, tirzepatide is the more effective FDA-approved option available today. For patients in good clinical status who can wait, retatrutide may offer a meaningful efficacy upgrade in 2–3 years.

Who Should Choose Which Drug?

Consider tirzepatide (Zepbound) when:

• Treatment is needed now (the only one of the two that is available)
• Weight-loss target is ≤20% of body weight
• Patient has established cardiovascular disease and benefits from emerging GLP-1 class CV signals
• Patient prefers a drug with longer post-marketing safety data
• Insurance coverage favors Zepbound

Consider waiting for retatrutide when:

• Tirzepatide has failed to produce adequate response (the GLP-1 resistance phenotype)
• Weight-loss target exceeds 25% of body weight
• Patient has significant MASLD/MASH and could benefit from the larger liver-fat effect
• Patient is in a clinical trial eligibility window for TRIUMPH

Combination and Sequencing

There is no current evidence supporting combining tirzepatide and retatrutide, and the GLP-1 class does not stack. Sequential use — failure on tirzepatide followed by retatrutide — is the more likely real-world scenario, and will be defined once retatrutide's label and switching guidance are issued.

Key Takeaways

• Retatrutide is mechanistically more potent because it adds glucagon receptor activity to the dual GLP-1/GIP backbone, increasing energy expenditure on top of appetite suppression.
• Phase 2 retatrutide produced ~24% weight loss at 48 weeks, exceeding tirzepatide's ~21% at 72 weeks in SURMOUNT-1. Phase 3 TRIUMPH data continues to support this lead.
• Retatrutide cuts liver fat by ~82% — the largest pharmacological effect ever reported for MASLD.
• Safety signals to watch with retatrutide: a 6–7 bpm heart-rate increase and dose-dependent glycemic shifts from glucagon activation.
• Approval gap: tirzepatide is available now; retatrutide is unlikely to reach the FDA before late 2027.
• For patients ready to start treatment, tirzepatide remains the standard of care. For those who can wait, retatrutide may become the new ceiling for obesity pharmacotherapy.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038

3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. DOI: 10.1038/s41591-024-03018-2

4. Rubino DM, Greenway FL, Khalid U, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27(3):967-978. DOI: 10.1111/dom.16176

5. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. DOI: 10.1016/S0140-6736(23)01053-X

Last updated: 2026-05-20 Medical review: Dr. James Chen, MD, PhD, FACE